PROCEPT BioRobotics Corporation Common Stock Q2 2026 Earnings Recap

PRCT Q2 2026 August 7, 2026

Get alerts when PRCT reports next quarter

Shares rose 5.2% post-earnings, reflecting market approval of stronger-than-expected system demand, notably robust HYDROS placements, and disciplined pricing that drove higher average selling prices.

Earnings Per Share Miss

$-0.47 vs $-0.46 est.

-1.8% surprise

Revenue Beat

94498000 vs 92771060 est.

+1.9% surprise

Market Reaction

1-Day +6.37%

5-Day +6.08%

See PRCT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue reached $94.5 million, up 19% year-over-year.
Procedure volume grew 21% to over 13,100 U.S. procedures; however, growth was softer than anticipated, driven by weaker legacy AQUABEAM account performance.
HYDROS system placements were strong with 65 units placed, including 50 new installs and 14 replacements, underscoring successful rollout efforts.
HYDROS average selling price increased to approximately $495,000, up from $485,000 in Q1 and $435,000 in full-year 2025.
Strategic commercial initiatives such as salesforce realignment, replacement upgrades, and patient activation pilots are underway to support sustainable growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PRCT on AllInvestView.

Previous Q1 2026